Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

Malaria Journal

Volumn 10, Issue , 2011, Pages

  Tommasi, Chiara ^a   Bellagamba, Rita ^a   Tempestilli, Massimo ^a   D'Avolio, Antonio ^b   Gallo, Anna L ^a   Ivanovic, Jelena ^a   Nicastri, Emanuele ^a   Pucillo, Leopoldo P ^a   Narciso, Pasquale ^c  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b AMEDEO DI SAVOIA HOSPITAL   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; ETRAVIRINE; MARAVIROC; RALTEGRAVIR; SAQUINAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIMALARIAL AGENT; ATOVAQUONE; ATOVAQUONE PROGUANIL; ATOVAQUONE-PROGUANIL; PROGUANIL; PYRIDAZINE DERIVATIVE;

ADULT; ARTICLE; BETA THALASSEMIA; CASE REPORT; CD4 LYMPHOCYTE COUNT; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALARIA; PROPHYLAXIS; PULMONARY HYPERTENSION; SALVAGE THERAPY; WASTING SYNDROME; CHEMISTRY; CHEMOPROPHYLAXIS; DRUG INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; PLASMA;

ADULT; ANTI-HIV AGENTS; ANTIMALARIALS; ATOVAQUONE; CHEMOPREVENTION; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALARIA; PLASMA; PROGUANIL; PYRIDAZINES; SAQUINAVIR;

EID: 79956189230     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-141     Document Type: Article

References (12)

1. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). AK Boggild ME Parise LS Lewis KC Kain, Am J Trop Med Hyg 2007 76 208 223 17297027 (Pubitemid 351627765)
2. Centers for Disease Control and Prevention, 2009 http://wwwnc.cdc.gov/ travel/destinations/kenya.aspx Travelers' Health. Yellow book Available at:
3. Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. M van Luin ME Van der Ende C Richter M Visser D Faraj A Van der Ven L Gelinck F Kroon FW Wit RH Van Schaik PF Kuks DM Burger, AIDS 2010 24 1223 1226 10.1097/QAD.0b013e3283389129 20299957
4. Clinical pharmacokinetics and pharmacodynamics of etravirine. M Schöller-Gyüre TN Kakuda A Raoof G De Smedt RM Hoetelmans, Clin Pharmacokinet 2009 48 561 574 10.2165/10895940-000000000-00000 19725591
5. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. CG Lee MM Gottesman CO Cardarelli M Ramachandra KT Jeang SV Ambudkar I Pastan S Dey, Biochemistry 1998 37 3594 3601 10.1021/bi972709x 9530286 (Pubitemid 28162914)
6. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. R Srinivas D Middlemas P Flynn A Fridland, Antimicrob Agents Chemother 1998 42 3157 3162 9835508 (Pubitemid 28553735)
7. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. M Iwamoto LA Wenning AS Petry M Laethem M De Smet JT Kost SA Merschman KM Strohmaier S Ramael KC Lasseter JA Stone KM Gottesdiener JA Wagner, Clin Pharm Ther 2008 83 293 299 10.1038/sj.clpt.6100281
8. Maraviroc: pharmacokinetics and drug interactions. S Abel DJ Back M Vourvahis, Antivir Ther 2009 14 607 618 19704163
9. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. NA Meanwell JF Kadow, Curr Opin Investig Drugs 2007 8 669 681 17668369 (Pubitemid 47205251)
10. A rare case of severe myopathy associated with etravirine use. C Tommasi M Tempestilli R Fezza R Bellagamba E Nicastri G D'offizi LP Pucillo P Narciso, AIDS 2010 24 1088 1090 10.1097/QAD.0b013e3283382f65 20386384
11. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other anti-retroviral agents in the plasma of HIV-infected patients. A D'Avolio L Baietto M Siccardi M Sciandra M Simiele V Oddone S Bonora G Di Perri, Ther Drug Monit 2008 30 662 669 10.1097/FTD. 0b013e318189596d 18824956
12. A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. A D'Avolio M Simiele L Baietto M Siccardi M Sciandra S Patanella S Bonora G Di Perri, Ther Drug Monit 2010 32 86 92 10.1097/FTD.0b013e3181cacbd0 20040898